RAS mutation-positive follicular variant of papillary thyroid carcinoma arising in a struma ovarii

Endocrine Pathology

Volumn 21, Issue 2, 2010, Pages 144-147

  Coyne, Christopher ^a   Nikiforov, Yuri E ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Ectopic thyroid cancer; Papillary thyroid carcinoma; Ras mutation; Struma ovarii; Thyroid cancer mutation

Indexed keywords

GLYCINE; GUANINE NUCLEOTIDE BINDING PROTEIN; LYSINE; PROTEIN HRAS; PROTEIN NRAS; RAS PROTEIN; UNCLASSIFIED DRUG; B RAF KINASE; BRAF PROTEIN, HUMAN; PROTEIN RET; RET PROTEIN, HUMAN;

ADULT; AMINO ACID SUBSTITUTION; ARTICLE; CASE REPORT; CODON; CYSTECTOMY; ECHOGRAPHY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INCIDENTAL FINDING; MICROSCOPY; MUTATIONAL ANALYSIS; OVARY TERATOMA; PATHOGENESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; THYROID FOLLICULAR CARCINOMA; THYROID PAPILLARY CARCINOMA; TREATMENT PLANNING; TUMOR LOCALIZATION; TUMOR VOLUME; ADENOCARCINOMA; GENETICS; MULTIPLE CANCER; MUTATION; OVARY TUMOR; PATHOLOGY; TERATOMA; THYROID TUMOR;

ADENOCARCINOMA, PAPILLARY; ADULT; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MUTATION; NEOPLASMS, MULTIPLE PRIMARY; OVARIAN NEOPLASMS; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-RET; RAS PROTEINS; STRUMA OVARII; THYROID NEOPLASMS;

EID: 77955909897     PISSN: 10463976     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12022-009-9097-8     Document Type: Article

References (25)

1. Makani S, Kim W, Gaba A. Struma ovarii with a focus of papillary thyroid cancer: a case report and review of the literature. Gynecol Oncol 94:835-9, 2004.
2. Logani S et al. Cystic ovarian metastasis from papillary thyroid carcinoma: a case report. Thyroid 11(11):1073-5, 2001.
3. Young R, Jackson A, Wells, M. Ovarian metastasis from thyroid carcinoma 12 years after partial thyroidectomy mimicking struma ovarii: report of a case. Int J Gynecol Pathol 13(2):181-5, 1994.
4. Flavin R et al. BRAF T1799A Mutation occurring in a case of malignant struma ovarii. Int J Surg Pathol 15(2):116-20, 2007.
5. Kimura ET et al. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/ PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 63:1454-7, 2003.
6. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 63:1454-7, 2003.
7. Soares P, Trovisco V, Rocha AS, Lima J, Castro P, Preto A, Maximo V, Botelho T, Seruca R, Sobrinho-Simoes M. BRAF mutations and RET/PTC rearrangements are alternative events in the etiopatho-genesis of PTC. Oncogene 22:4578-80, 2003.
8. Frattini M, Ferrario C, Bressan P, Balestra D, De Cecco L, Mondellini P, Bongarzone I, Collini P, Gariboldi M, Pilotti S, Pierotti MA, Greco A. Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer. Oncogene, 23(44):7436-40, 2004.
9. Cohen Y, Xing M, Mambo E, Guo Z, Wu G, Trink B, Beller U, Westra WH, Ladenson PW, Sidransky D. BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst 95:625-7, 2003.
10. Grieco M, Santoro M, Berlingieri MT, Melillo RM, Donghi R, Bongarzone I, Pierotti MA, Della Porta G, Fusco A, Vecchio G. PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell 60:557-63, 1990.
11. Bongarzone I, Butti MG, Coronelli S, Borrello MG, Santoro M, Mondellini P, Pilotti S, Fusco A, Della Porta G, Pierotti MA. Frequent activation of ret protooncogene by fusion with a new activating gene in papillary thyroid carcinomas. Cancer Res 54:2979-85, 1994.
12. Santoro M, Dathan NA, Berlingieri MT, Bongarzone I, Paulin C, Grieco M, Pierotti MA, Vecchio G, Fusco A. Molecular characterization of RET/PTC3; a novel rearranged version of the retproto-oncogene in a human thyroid papillary carcinoma. Oncogene 9:509-16, 1994.
13. Nikiforov YE. RET/PTC rearrangement in thyroid tumors. Endocr Pathol 13:3-16, 2002.
14. Namba H, Rubin SA, Fagin JA. Point mutations of ras oncogenes are an early event in thyroid tumorigenesis. Mol Endocrinol 4:1474-9, 1990.
15. Ezzat S, Zheng L, Kolenda J, Safarian A, Freeman JL, Asa SL. Prevalence of activating ras mutations in morphologically characterized thyroid nodules. Thyroid 6:409-16, 1996.
16. Zhu Z, Gandhi M, Nikiforova MN, Fischer AH, Nikiforov YE. Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma. An unusually high prevalence of ras mutations. Am J Clin Pathol 120:71-7, 2003.
17. Adeniran AJ, Zhu Z, Gandhi M, Steward DL, Fidler JP, Giordano TJ, Biddinger PW, Nikiforov YE. Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. Am J Surg Pathol 30:216-22, 2006.
18. Nikiforov YE. Thyroid carcinoma: molecular pathways and therapeutic targets. Mod Path 21:537-43, 2008.
19. Golbert L. H-RAS gene expression in human multinodular goiter. Histol Histopathol 22:409-16, 2007.
20. Davis, KP et al. Primary ovarian carcinoid tumors. Gynecol Oncol 61: 259-65, 1996.
21. Cyniak-Magierska A et al. Prevalence of RAS point mutations in papillary thyroid carcinoma: a novel mutation at codon 31 of K-RAS. Exp Clin Endocrinol Diabetes 115:594-9, 2007.
22. Hara H et al. N-ras mutation: an independent prognostic factor for aggressiveness of papillary thyroid carcinoma. Surgery 116 (6):1010-6, 1994.
23. Roth L, Talerman A. The Enigma of Struma Ovarii. Pathology 39 (1):139-46, 2007.
24. Cicarelli A et al. Thyrotoxic adenoma followed by atypical hyperthyroidism due to struma ovarii: clinical and genetic studies. Eur J Endocrinol 150:431-7, 2004.
25. Suarez, HG. Genetic alterations in human epithelial thyroid tumours. Clin Endocrinol 48:531-46, 1998.